Pregnancy & Lactation : הריון/הנקה

4.6 Fertility, pregnancy and lactation
Pregnancy
Data obtained from a limited number of exposed pregnancies indicate that atropine has no adverse effects on pregnancy or on the health of the fetus/newborn.
Animal studies do not indicate direct or indirect harmful effects of reproductive toxicity (see section 5.3).
Studies of the pharmacokinetics of atropine in mothers and fetuses in late stage pregnancies indicate that atropine rapidly crosses the placental barrier. Intravenous administration of atropine during pregnancy or at the end of pregnancy may cause tachycardia in the fetus and in the mother.
Atropine should not be used during pregnancy, unless clearly needed.
Lactation
Small amounts of atropine may pass into human breast milk. Newborns have a greater sensitivity to the anticholinergic effects of atropine. Atropine may inhibit milk production, particularly in case of repeated use. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from treatment, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. If you decide to continue breast-feeding during treatment, your child should be monitored for the presence of anticholinergic effects.
Fertility
No data is available on the effects of atropine sulfate on fertility in humans. Atropine sulfate has reduced the fertility of male rats, presumably as a result of the inhibitory effect on the transport of sperm and ejaculation.